An estimated 2·1 billion adults worldwide are affected by overweight and obesity, a figure projected to reach 3·8 billion by ...

During a weeklong joint operation between U.S. Customs and Border Protection and U.S. Food and Drug Administration, CBP officers inspected hundreds of boxes containing possible counterfeit and ...

The former This Morning presenter, 63, has long been open about her struggles with her weight, which have seen her fluctuate ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these findings, a clear link has yet to be established, and much of the evidence remains ...

Uncover the truth about GLP-1 weight loss drugs like Ozempic and Mounjaro. Learn how they work, who benefits most, potential risks, and why experts say they can be game-changing tools for fighting ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

Yesterday, US pharmaceutical giant Lilly announced the cost would soar from September 1, with a month's supply of the highest ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health ...

I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...